Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Sebi Considers 'Guardrails' for IPO Valuations to Protect Retail Investors

IPO

|

Updated on 07 Nov 2025, 09:39 am

Whalesbook Logo

Reviewed By

Akshat Lakshkar | Whalesbook News Team

Short Description:

Securities and Exchange Board of India (Sebi) member Kamlesh Varshney indicated the need for stronger 'guardrails' to protect retail investors from potentially inflated Initial Public Offering (IPO) valuations. While stating it's not a regulatory gap, Sebi aims to improve the effectiveness of anchor investment valuations. Varshney also identified valuations in corporate arrangements as a potential regulatory gap needing future guidelines, possibly in conjunction with the Insolvency and Bankruptcy Board of India. This follows Sebi Chairman Tuhin Kanta Pandey's reiteration that the regulator does not intervene in IPO pricing.
Sebi Considers 'Guardrails' for IPO Valuations to Protect Retail Investors

▶

Detailed Coverage:

Sebi whole-time member Kamlesh Varshney stated that while the market regulator is moving away from controlling capital issue valuations, there is a need to implement 'guardrails' to safeguard retail investors. He noted that retail investors have frequently challenged IPO valuations, suggesting that while not a regulatory gap, enhanced mechanisms are required to ensure anchor investment valuations are performed properly, effectively, and efficiently. This sentiment aligns with Sebi Chairman Tuhin Kanta Pandey's recent remarks that the regulator will not set IPO valuations, which are ultimately determined by investors.

Varshney also pointed out a potential regulatory gap in the 'valuation during corporate arrangements', where promoter shareholders might receive inflated prices detrimental to minority shareholders. He suggested that Sebi might need to develop guidelines for such valuations, possibly in collaboration with another regulator, IBBI (Insolvency and Bankruptcy Board of India), similar to transfer pricing guidelines.

Impact: This news suggests increased regulatory focus on IPO pricing fairness. It may lead to more conservative IPO pricing or enhanced disclosure requirements, potentially affecting the volume and speed of upcoming IPOs. For retail investors, it signifies an effort to reduce the risk of investing in overvalued companies. New guidelines for corporate arrangement valuations could impact mergers and acquisitions.

Rating: 7/10

Difficult Terms: IPO (Initial Public Offering): The first time a private company offers its shares to the public to raise capital. Guardrails: Safety measures or guidelines implemented to prevent negative outcomes or manage risks. Retail Investors: Individual investors buying securities for their own accounts. Anchor Investments: Investments made by large institutional investors before an IPO opens to the public, aiming to build confidence. Corporate Arrangements: Transactions or agreements between companies, such as mergers or acquisitions. Transfer Pricing: The prices charged for goods, services, or assets transferred between related entities within a multinational company. IBBI (Insolvency and Bankruptcy Board of India): A regulatory body overseeing insolvency resolution processes in India.


Banking/Finance Sector

AU Small Finance Bank Launches 'M' Circle, a Tailored Banking Proposition for Women

AU Small Finance Bank Launches 'M' Circle, a Tailored Banking Proposition for Women

Finance Minister Urges Public Banks to Embrace Local Languages and Simplify Loan Processes

Finance Minister Urges Public Banks to Embrace Local Languages and Simplify Loan Processes

JioBlackRock CEO Advocates for 'Wealth Inclusion' in India, Urging Broader Access to Fiduciary Advice

JioBlackRock CEO Advocates for 'Wealth Inclusion' in India, Urging Broader Access to Fiduciary Advice

Piramal Finance Lists with Strong Upper Circuit, Signals Investor Confidence Post-Merger

Piramal Finance Lists with Strong Upper Circuit, Signals Investor Confidence Post-Merger

NPCI Unveils Plan for UPI-Powered Credit Revolution with Unified Lending Interface

NPCI Unveils Plan for UPI-Powered Credit Revolution with Unified Lending Interface

India Accelerates Plan to Create Global-Scale Banks Through PSB Consolidation

India Accelerates Plan to Create Global-Scale Banks Through PSB Consolidation

AU Small Finance Bank Launches 'M' Circle, a Tailored Banking Proposition for Women

AU Small Finance Bank Launches 'M' Circle, a Tailored Banking Proposition for Women

Finance Minister Urges Public Banks to Embrace Local Languages and Simplify Loan Processes

Finance Minister Urges Public Banks to Embrace Local Languages and Simplify Loan Processes

JioBlackRock CEO Advocates for 'Wealth Inclusion' in India, Urging Broader Access to Fiduciary Advice

JioBlackRock CEO Advocates for 'Wealth Inclusion' in India, Urging Broader Access to Fiduciary Advice

Piramal Finance Lists with Strong Upper Circuit, Signals Investor Confidence Post-Merger

Piramal Finance Lists with Strong Upper Circuit, Signals Investor Confidence Post-Merger

NPCI Unveils Plan for UPI-Powered Credit Revolution with Unified Lending Interface

NPCI Unveils Plan for UPI-Powered Credit Revolution with Unified Lending Interface

India Accelerates Plan to Create Global-Scale Banks Through PSB Consolidation

India Accelerates Plan to Create Global-Scale Banks Through PSB Consolidation


Healthcare/Biotech Sector

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies